Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;22(2):77-84.
doi: 10.1007/s11892-022-01448-1. Epub 2022 Feb 12.

Contraception for Adolescents and Young Women with Type 2 Diabetes-Specific Considerations

Paulina M Merino  1 , Ethel Codner  2
Affiliations
Review

Contraception for Adolescents and Young Women with Type 2 Diabetes-Specific Considerations

Paulina M Merino et al. Curr Diab Rep. 2022 Feb.

Abstract

Purpose of review: This article reviews how to address contraception in young women with type 2 diabetes (T2D). The presence of obesity and comorbidities associated with insulin resistance increases the risk of thromboembolic disease and adverse cardiovascular outcomes.

Recent findings: Recent studies have shown that adolescents with T2D are at high risk of unintended pregnancy with poor outcomes for the mother and offspring. Adolescents with T2D without severe obesity, micro- or macrovascular disease, or other cardiovascular risk factors can use any contraceptive method. However, only nonhormonal or progestin-only methods may be used when morbid obesity, severe hypertension, micro- or macrovascular disease, or multiple cardiovascular risk factors are present. The medical team must provide preconceptional counseling and contraception to reduce adolescent pregnancies in young women with T2D. Progestin-only or nonhormonal long-acting reversible contraception (LARC) should be recommended for women with T2D with compliance issues or adverse cardiovascular risk profiles.

Keywords: Adolescents; Contraception; Hormonal contraception; Long-acting reversible contraceptive; Obesity; Type 2 diabetes.

PubMed Disclaimer

References

    1. Koren D, Levitsky LL. Type 2 diabetes mellitus in childhood and adolescence. Pediatr Rev. 2021;42(4):167–79. https://doi.org/10.1542/pir.2019-0236 . - DOI - PubMed
    1. Kohn JR, Rajan SS, Kushner JA, Fox KA. Outcomes, care utilization, and expenditures in adolescent pregnancy complicated by diabetes. Pediatr Diabetes. 2019;20(6):769–77. https://doi.org/10.1111/pedi.12871 . - DOI - PubMed
    1. Klingensmith GJ, Pyle L, Nadeau KJ, Barbour LA, Goland RS, Willi SM, et al. Pregnancy outcomes in youth with type 2 diabetes: the TODAY study experience. Diabetes Care. 2016;39(1):122–9. https://doi.org/10.2337/dc15-1206 . - DOI - PubMed
    1. Barbour LA. Changing perspectives in pre-existing diabetes and obesity in pregnancy: maternal and infant short- and long-term outcomes. Curr Opin Endocrinol Diabetes Obes. 2014;21(4):257–63. https://doi.org/10.1097/MED.0000000000000079 . - DOI - PubMed
    1. Catalano PM, Farrell K, Thomas A, Huston-Presley L, Mencin P, de Mouzon SH, et al. Perinatal risk factors for childhood obesity and metabolic dysregulation. Am J Clin Nutr. 2009;90(5):1303–13. https://doi.org/10.3945/ajcn.2008.27416 . - DOI - PubMed - PMC

Publication types

LinkOut - more resources